RenovoRx’s Innovative Approach in Pancreatic Cancer Treatment: A Clinical Study Update

Renovorx, Inc. ((RNXT)) announced an update on their ongoing clinical study.

RenovoRx, Inc. (RNXT) is conducting a clinical study titled ‘Targeted Intra-arterial Gemcitabine vs. Continuation of IV Gemcitabine Plus Nab-Paclitaxel Following Induction With Sequential IV Gemcitabine Plus Nab-Paclitaxel and Radiotherapy for Locally Advanced Pancreatic Cancer.’ The study aims to evaluate the efficacy of intra-arterial gemcitabine compared to the continuation of intravenous gemcitabine plus nab-paclitaxel in patients with locally advanced pancreatic cancer that is not amenable to surgery. This research is significant as it explores potential improvements in treatment outcomes for a challenging cancer type.

The interventions being tested include intra-arterial administration of gemcitabine using the RenovoCath device and intravenous administration of gemcitabine and nab-paclitaxel. The goal is to determine whether the targeted delivery of chemotherapy can enhance treatment efficacy.

This Phase 3 study is designed as a multi-center, open-label, randomized, active-controlled trial. Participants with stable or responding disease after induction therapy are randomly assigned to either the experimental or control group. The primary purpose of the study is treatment, and there is no masking involved.

The study began on August 17, 2017, and is currently recruiting participants. The last update was submitted on April 10, 2025. These dates are crucial as they indicate the study’s progress and ongoing nature.

The outcome of this study could significantly impact RenovoRx’s stock performance and investor sentiment, especially if the intra-arterial approach proves more effective. This could position RenovoRx as a leader in innovative cancer treatments, potentially affecting competitors in the oncology sector.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.